

Figure 1 - Mean HbA1c (%) by visit – mITT population




Number of subjects								
INS/LIXI	468	468	468	461	455	447	443	467
INS	466	466	466	456	455	447	446	464
LIXI	232	233	233	224	224	221	221	233

Figure 2 - Mean change in HbA1c (%) from baseline by visit – mITT population




Number of subjects						
INS/LIXI	468	461	455	447	443	467
INS	466	456	455	447	446	464
LIXI	233	224	224	221	221	233

Figure 3 – Mean body weight (kg)



Number of subjects								
INS/LIXI	468	464	460	456	453	451	448	467
INS	466	457	456	456	449	449	446	465
LIXI	233	228	225	225	226	223	222	233


Figure 4 – Mean fasting plasma glucose (mmol/L/[mg/dL]) by visit – mITT population



Number of subjects


INS/LIXI	463	466	468	453	457	455	440	436	466
INS	464	464	466	455	457	451	443	438	465
LIXI	232	231	233	227	222	224	221	216	232

Figure 5 – Mean fasting plasma glucose (mmol/L/[mg/dL]) from baseline by visit – mITT population




Number of subjects							
INS/LIXI	468	453	457	455	440	436	466
INS	466	455	457	451	443	438	465
LIXI	233	227	222	224	221	216	232

Figure 6 - Mean 7-point SMPG (mmol/L/[mg/dL]) at baseline and Week 30



Number of subjects							
INS/LIXI at baseline	459	452	447	454	448	445	418
INS at baseline	451	444	441	441	438	436	404
LIXI at baseline	226	226	221	224	223	222	206
INS/LIXI at Week 30	383	380	378	379	374	377	355
INS at Week 30	371	363	359	361	359	355	333
LIXI at Week 30	185	180	182	182	181	180	166

Figure 7 – Mean average daily insulin glargine dose (U) by visit



Number of subjects																		
INS/LIXI	462	466	459	461	457	455	438	422	433	421	441	424	450	449	440	441	433	438	467
INS	457	457	454	456	449	452	439	423	421	420	439	429	442	447	443	447	440	440	463

Figure 8 – Graphical Study Design of Example 2





Figure 9 - Plot of mean HbA1c (%) by visit – mITT population



Number of subjects								
INS/LIXI	366	366 366	357	357	348	346	364
INS	365	365 365	356	360	354	355	364

Figure 10 - Plot of mean change in HbA1c (%) from baseline by visit – mITT population






Figure 11 - Plot of mean change in body weight (kg) from baseline by visit – mITT population



Number of subjects								
INS/LIXI	366	358	358	359	351	350	348	365
INS	365	361	361	362	357	358	357	365

Figure 12 - Plot of mean 7-point SMPG at baseline and Week 30 – mITT population



Number of subjects							
INS/LIXI at baseline	354	349	346	347	348	345	325
INS at baseline	349	343	338	345	340	338	322
INS/LIXI at Week 30	303	299	298	300	296	298	276
INS at Week 30	309	301	298	302	301	295	278

Figure 13 - Plot of mean daily insulin glargine dose (U) by visit – mITT population






Figure 14 - Plot of mean fasting plasma glucose by visit – mITT population



Number of subjects									
INS/LIXI	364	363	366	358	355	355	347	341	364
INS	360	360	365	359	353	357	356	349	364

Figure 15 – Graphical Study Design of Example 1



Phone call visit: Additional phone call for titration purposes should be scheduled as often as deemed necessary by the investigator

on site visit

Ⓡ 1:1 randomization stratified by values of HbA1c (<8%, ≥8%) and metformin use (Y, N).